Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr, a potential treatment for complicated urinary tract infections.
https://www.pharmalive.com/wp-content/uploads/2021/04/FDA-Approves-GSK’s-Checkpoint-Inhibitor-Jemperli-for-Endometrial-Cancer-BioSpace-4-23-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-22 10:48:022022-09-22 10:48:02GSK steps in to save Spero, late-stage antibiotic